Spero Therapeutics, Inc. (SPRO)

Market Cap	42.85M
Revenue (ttm)	47.98M
Net Income (ttm)	-68.57M
Shares Out	55.90M
EPS (ttm)	-1.27
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	286,860
Open	0.8500
Previous Close	0.8601
Day's Range	0.7641 - 0.8500
52-Week Range	0.7300 - 1.8100
Beta	0.69
Analysts	Buy
Price Target	5.00 (+552.32%)
Earnings Date	Mar 27, 2025

About SPRO

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant e...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 2, 2017
• Employees: 46
• Stock Exchange: NASDAQ
• Ticker Symbol: SPRO
• Website: https://sperotherapeutics.com

Analyst Forecast

According to 4 analysts, the average rating for SPRO stock is "Buy." The 12-month stock price forecast is $5.0, which is an increase of 552.32% from the latest price.

Price Target

$5.0

(552.32% upside)

Analyst Consensus: Buy